Key Events This Week
16 Feb: Stock rallies 3.17% on strong volume
17 Feb: Sharp 33.1% surge in open interest amid mixed price action
18 Feb: Heavy put option activity signals bearish sentiment
18 Feb: Open interest rises 13.7% despite price decline
19 Feb: Technical momentum shifts to mildly bullish
20 Feb: Week closes at Rs.1,159.75, down 1.36% on final day
16 February: Strong Opening Rally on Elevated Volume
Aurobindo Pharma began the week on a positive note, surging 3.17% to close at Rs.1,184.90 on 16 February 2026. This rally was supported by robust volume of 1,21,222 shares, signalling renewed buying interest. The Sensex also gained 0.70%, closing at 36,787.89, but Aurobindo outperformed the benchmark significantly. The stock’s intraday high and closing price near the upper end of its recent trading range suggested short-term bullish momentum. This strong start set the tone for heightened market activity in the days ahead.
17 February: Open Interest Surges Amid Mixed Price Action
On 17 February, Aurobindo Pharma’s derivatives segment saw a sharp 33.1% increase in open interest, rising to 86,234 contracts from 64,808 the previous day. Despite this surge, the stock price marginally declined by 0.02% to Rs.1,184.65, underperforming the Pharmaceuticals & Biotechnology sector’s 0.40% gain and the Sensex’s 0.32% rise. The futures segment alone accounted for a notional value of approximately ₹2,09,099 lakhs, while options contributed ₹39,395.5 crores, reflecting intense speculative activity.
This divergence between derivatives activity and spot price suggests complex positioning, with traders possibly hedging or speculating on volatility rather than outright bullish bets. Technical indicators showed the stock trading above its 5-day, 20-day, 100-day, and 200-day moving averages but below the 50-day average, indicating a consolidation phase. Delivery volumes dropped sharply by 47.24%, reinforcing cautious sentiment among long-term holders.
Turnaround taking shape! This Small Cap from NBFC sector just hit profitability with strong business fundamentals showing up. Catch it before the major breakout happens!
- - Recently turned profitable
- - Strong business fundamentals
- - Pre-breakout opportunity
18 February: Bearish Put Option Surge and Rising Open Interest
The 18th of February marked a notable shift as Aurobindo Pharma became the most active stock in put option trading ahead of the 24 February expiry. A total of 6,072 put contracts at the 1,100 strike price were traded, with a turnover of approximately ₹369.36 lakhs. Open interest at this strike stood at 2,174 contracts, indicating sustained bearish positioning or hedging activity.
The stock price declined sharply by 4.14% to close at Rs.1,143.80, underperforming its sector by 2.96%. Intraday lows touched Rs.1,129.20, a 4.85% drop from the previous close. Technically, the stock traded below its 5-day, 20-day, 50-day, and 100-day moving averages but remained above the 200-day average, signalling short- to medium-term weakness despite long-term support.
Simultaneously, open interest in derivatives rose by 13.7% to 74,214 contracts, accompanied by a total volume of 84,831 contracts. The futures segment accounted for ₹79,720.6 lakhs in value, while options contributed ₹46,459.4 crores, underscoring significant speculative and hedging interest amid the price decline. This combination of rising open interest and falling prices typically signals bearish conviction among traders.
19 February: Technical Momentum Shifts to Mildly Bullish
Following the previous day’s decline, Aurobindo Pharma rebounded on 19 February, gaining 1.38% to close at Rs.1,175.75. This recovery occurred despite the Sensex falling 1.45%, highlighting relative strength. Technical momentum shifted from mildly bearish to mildly bullish, supported by daily moving averages aligning positively and price trading above key short-term averages.
However, weekly and monthly momentum oscillators such as MACD and KST remained mildly bearish, indicating that longer-term momentum was still restrained. Bollinger Bands on the weekly chart turned bullish, reflecting increased volatility favouring buyers, while monthly bands remained bearish. On-Balance Volume showed mild bullishness on the monthly timeframe, suggesting gradual accumulation.
This mixed technical picture suggests a transitional phase, with short-term optimism tempered by caution over broader trends. The stock’s Mojo Score remained at 58.0 with a Hold rating, reflecting tempered expectations amid these mixed signals.
Holding Aurobindo Pharma Ltd. from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
20 February: Week Closes with a Slight Decline Amid Mixed Signals
On the final trading day of the week, Aurobindo Pharma declined 1.36% to close at Rs.1,159.75 on relatively low volume of 28,911 shares. The Sensex gained 0.41%, closing at 36,674.32, indicating the stock underperformed the benchmark on the day. This final dip capped a week of volatile swings, with the stock ending modestly higher overall but showing signs of short-term uncertainty.
Technical indicators suggest the stock remains in a consolidation phase, with mixed momentum signals and a Hold mojo grade. The interplay of rising open interest, heavy put option activity, and fluctuating price action points to a market balancing between cautious optimism and hedging against downside risks.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-02-16 | Rs.1,184.90 | +3.17% | 36,787.89 | +0.70% |
| 2026-02-17 | Rs.1,184.65 | -0.02% | 36,904.38 | +0.32% |
| 2026-02-18 | Rs.1,159.75 | -2.10% | 37,062.35 | +0.43% |
| 2026-02-19 | Rs.1,175.75 | +1.38% | 36,523.88 | -1.45% |
| 2026-02-20 | Rs.1,159.75 | -1.36% | 36,674.32 | +0.41% |
Key Takeaways
1. Mixed Market Sentiment: The week was characterised by a tug-of-war between bullish technical signals and bearish derivatives positioning, reflected in the sharp open interest surges and heavy put option volumes.
2. Volatility and Volume Dynamics: Elevated volumes on 16 and 17 February contrasted with subdued activity on the final day, indicating fluctuating investor conviction and cautious trading ahead of expiry dates.
3. Technical Momentum Transition: The shift from mildly bearish to mildly bullish momentum midweek suggests a tentative recovery, though longer-term indicators remain cautious.
4. Derivatives Activity as a Sentiment Barometer: Rising open interest amid falling prices on 18 February signals bearish conviction, while the rebound on 19 February highlights the complex interplay of speculative and hedging strategies.
5. Hold Rating and Mojo Score: The Hold mojo grade of 58.0, downgraded from Buy in December 2025, aligns with the mixed signals and advises a measured approach to the stock in the near term.
Conclusion
Aurobindo Pharma’s performance over the week ending 20 February 2026 underscores a market environment marked by active repositioning and cautious optimism. The stock’s modest 0.98% gain outpaced the Sensex, yet the underlying technical and derivatives data reveal a nuanced picture of investor sentiment. Sharp increases in open interest and put option activity point to heightened hedging and speculative positioning, while technical momentum indicators suggest a tentative shift towards bullishness tempered by longer-term caution.
Investors should remain attentive to evolving volume patterns, open interest trends, and key technical levels as the stock navigates this consolidation phase. The Hold mojo rating reflects the need for confirmation of sustained strength before a more decisive trend emerges. Overall, Aurobindo Pharma’s week was a study in contrasts, balancing between potential upside and guarded risk management amid a complex market backdrop.
Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →
